Clinical Trial Update: Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating allogeneic second-generation CD19-CAR T cells for pediatric relapsed/refractory B-cell acute lymphoblastic leukemia is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Allogeneic CD19-CAR T cells (second generation) (CD19-CAR T cells)

Snippet

Sponsor: Bambino Gesù Hospital and Research Institute | Conditions: B-cell Acute Lymphoblastic Leukemia | Phase 1 | Status: RECRUITING